Details of the Drug
General Information of Drug (ID: DMWZ093)
| Drug Name |
ANTHRONE
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
ANTHRONE; 90-44-8; 9(10H)-Anthracenone; Carbothrone; Anthranone; 9-Oxoanthracene; 9,10-Dihydro-9-oxoanthracene; 10H-anthracen-9-one; anthracen-9(10H)-one; Az-O; Anthracene, 9,10-dihydro-9-oxo-; UNII-FP0FJ7K744; CCRIS 3175; CHEBI:33835; HSDB 2158; NSC 1965; EINECS 201-994-0; AI3-11256; FP0FJ7K744; CHEMBL124440; 9-10-dihydro-9-oxoanthracene; 9,10-Dihydro-9-ketoanthracene; RJGDLRCDCYRQOQ-UHFFFAOYSA-N; MFCD00001187; Anthrone, ACS reagent; Anthrone, 95%, pure; 10-hydroanthracen-9-one; A-8100; 9-anthrone; Anthrone, 96%; AC1L1NTG
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 194.23 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 3.7 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


